A Phase 2a, Randomized, Double-blind, Placebo-controlled Assessment of the Safety and Protective Efficacy of FF-3 Dry Powder Administered by Nasal Inhalation for 5 Days to Healthy Adult Subjects Who Are Experimentally Infected With a Challenge Strain of Influenza A Virus

Trial Profile

A Phase 2a, Randomized, Double-blind, Placebo-controlled Assessment of the Safety and Protective Efficacy of FF-3 Dry Powder Administered by Nasal Inhalation for 5 Days to Healthy Adult Subjects Who Are Experimentally Infected With a Challenge Strain of Influenza A Virus

Completed
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Flufirvitide-3 (Primary)
  • Indications Influenza virus infections
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Autoimmune Technologies
  • Most Recent Events

    • 21 Jun 2016 Status changed from active, no longer recruiting to completed.
    • 14 Jun 2016 Planned End Date changed from 1 Jun 2016 to 1 Jul 2016.
    • 14 Jun 2016 Planned primary completion date changed from 1 Apr 2016 to 1 Jul 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top